Patterns of asthma-related health care resource use in children treated with montelukast or fluticasone

Current Medical Research and Opinion

Volumn 22, Issue 8, 2006, Pages 1453-1461

  Allen Ramey, Felicia C ^a   Markson, Leona E ^a   Riedel, Aylin A ^b   Sajjan, Shiva ^a   Weiss, Kevin B ^c,d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Ingenix Inc   (United States)

^c HINES VA HOSPITAL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Asthma; Asthma controller; Comparative study; Drug therapy; Fluticasone; Montelukast; Propensity score; Therapeutic use

Indexed keywords

FLUTICASONE; MONTELUKAST;

ADOLESCENT; ASTHMA; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; EMERGENCY CARE; EMERGENCY WARD; FEMALE; HEALTH CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; RISK FACTOR; SCHOOL CHILD;

ACETATES; ADOLESCENT; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; DELIVERY OF HEALTH CARE; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; MALE; MEDICATION SYSTEMS; PHARMACEUTICAL SERVICES; QUINOLINES; RETROSPECTIVE STUDIES;

EID: 33748087084     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X115522     Document Type: Conference Paper

References (54)

1. Guilbert TW, Morgan WJ, Krawiec M, et al. The prevention of early asthma in kids study: design, rationale and methods for the Childhood Asthma Research and Education network. Control Clin Trials 2004;25:286-310
2. Wainwright C, Isles AF, Francis PW. Asthma in children. Med J Aust 1997;167:218-23
3. Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995;332:133-8
4. National Asthma Education and Prevention Program. Expert Panel Report: guidelines for the diagnosis and management of asthma update on selected topics - 2002. J Allergy Clin Immunol 2002;110:S141-219
5. National Heart Lung and Blood Institute, World Health Organization. Global strategy for asthma management and prevention. Update from NHLB/WHO Workshop Report 1995. GINA.NIH Publication No. 02-3659, 2002
6. National Center for Health Statistics. Asthma prevalence, health care use and mortality, 2000-2001. Available from http://www. cdc.gov/nchs/products/ pubs/pubd/hestats/asthma/asthma.htm [Last accessed 7 June 2003]
7. Mannino DM, Homa DM, Akinbami IJ, et al. Surveillance for asthma - United States, 1980-1999. MMWR Surveill Summ 2002;51:1-13
8. Donahue JG, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997;277:887-91
9. Schatz, M, Nakahiro R, Crawford W, et al. Asthma quality-of-care markers using administrative data. Chest 2005;128:1968-73
10. Schatz, M, Nakahiro R, Jones CH, et al. Asthma population management: development and validation of a practical 3-level risk stratification scheme. Am J Manag Care 2004;10:25-32
11. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 2001;107:3-8
12. American Lung Association Epidemiology and Statistics Unit. Trends in asthma morbidity and mortality. Research and Scientific Affairs. March 2003
13. Halterman JS, Aligne CA, Auinger P, et al. Inadequate therapy for asthma among children in the United States. Pediatrics 2000;105:272-6
14. Williams SG, Schmidt DK, Redd SC, et al. Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program. MMWR Recomm Rep 2003;52:1-8
15. Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ 2003;326:621
16. Price DB, Ben-Joseph RH, Zhang Q. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K. Respir Med 2001;95:83-9
17. Bukstein DA, Henk HJ, Luskin AT. A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy. Clin Ther 2001;23:1589-600
18. Stempel DA, Mauskopf J, McLaughlin T, et al. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 2001;95:227-34
19. Allen-Ramey FC, Duong PT, Goodman DC, et al. Outcomes of patients treated with fluticasone propionate or montelukast sodium. Manag Care Interface 2003;16:30-5
20. Allen-Ramey FC, Duong PT, Goodman DC, et al. Treatment effectiveness of inhaled corticosteroids and leukotriene modifiers for patients with asthma: an analysis from managed care data. Allergy Asthma Proc 2003;24:43-51
21. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004;113:245-51
22. Orsini L, Limpa-Amara S, Crown WH, et al. Asthma hospitalisation risk and costs for patients treated with fluticasone propionate vs montelukast. Ann Allergy Asthma Immunol 2004;92:523-9
23. Pathak DS, Davis EA, Stanford RH. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. Pharmacotherapy 2002;22:166-74
24. Stempel DA, Meyer JW, Stanford RH, et al. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol 2001;107:94-8
25. Stempel DA, O'Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002;109:433-9
26. Stempel DA, Kelly HW. Approaching value in asthma management: the need to integrate clinical and economic-research with the basic science. J Allergy Clin Immunol 2002;109:S503-10
27. Quam L, Ellis LB, Venus P, et al. Using claims data loi epidemiologic research. The concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population. Med Care 1993;31:498-507
28. Allen-Ramey FC, Duong PT, Riedel AA, et al. Observational study of the effects of montelukast and fluticasone in subjects matched at baseline. Ann Allergy Asthma Immunol 2004;93:373-80
29. Parsons LS. Reducing bias in a propensity score matched-pair sample using Greedy matching techniques. Proceedings of the twenty-sixth annual SAS users group international conference, Cary, NC: SAS Institute Inc., 2001. Available from http://www2.sas.com/proceedings/sugi26/p214-26.pdf [Last accessed 19 June 2006]
30. Jones C, Santanello NC, Boccuzzi SJ, et al. Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data. J Asthma 2003;40:93-101
31. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998;279:1181-6
32. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108:E48
33. Davies GM, Dasbach EJ, Santanello NC, et al. The effect of montelukast versus usual care on health care resource utilization in children aged 2 to 5 years with asthma. Clin Ther 2004;26:1895-904
34. Adams N, Bestall J, Malouf R, et al. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2005;(1):CD002738
35. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998;158:1213-20
36. MacKenzie CA, Weinberg EG, Tabachnik E, et al. A placebo controlled trial of fluticasone propionate in asthmatic children. Eur J Pediatr 1993;152:856-60
37. Hoekstra MO, Grol MH, Bouman K, et al. Fluticasone propionate in children with moderate asthma. Am J Respir Crit Care Med 1996;154:1039-44
38. Peden DB, Berger WE, Noonan MJ, et al. Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma. J Allergy Clin Immunol 1998;102:32-8
39. Teper AM, Colom AJ, Kofman CD, et al. Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing. Pediatr Pulmonol 2004;37:111-5
40. Zeiger RS, Bird SR, Kaplan MS, et al. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med 2005;118:649-57
41. Kanniess F, Richter K, Bohme S, et al. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J 2002;20:853-8
42. Busse W, Raphael GD, Galant S, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001;107:461-8
43. Ostrom NK, Decotiis BA, Lincourt WR, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr 2005;147:213-20
44. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005;115:233-42
45. Maspero JF, Duenas-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin 2001;17:96-104
46. Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005;171:315-22
47. Garcia Garcia ML, Wahn U, Gilles L, et al. Montelukast, compared with fluticasone, for control of asthma among 6-to 14-year old patients with mild asthma: The MOSAIC study. Pediatrics 2005;116:360-9
48. Bauman LJ, Wright E, Leickly FE, et al. Relationship of adherence to pediatric asthma morbidity among inner-city children. Pediatrics 2002;110:E6
49. Lozano P, Finkelstein JA, Hecht J, et al. Asthma medication use and disease burden in children in a primary care population. Arch Pediatr Adolesc Med 2003;157:81-8
50. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004;114:1288-93
51. Leickly FE, Wade SL, Crain E, et al. Self-reported adherence, management behavior, and barriers to care after an emergency department visit by inner city children with asthma. Pediatrics 1998;101:E8
52. Gillissen A. Managing asthma in the real world. Int J Clin Pract 2004;58:592-603
53. Sherman J, Patel P, Hutson A, et al. Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma. Pharmacotherapy 2001;21:1464-7
54. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994;154:1349-52